Prevalence and distribution of human papillomavirus findings in swab specimens from gynaecology clinics of the east coast of Spain

Scandinavian Journal of Infectious Diseases

Volumn 42, Issue 6-7, 2010, Pages 549-553

  Martorell, Miguel ^a   Garca Garca, José Ángel ^a   Ortiz, Cristian ^a   Pérez Vallés, Ana ^a   Calabuig, Consuelo ^a   Gómez Cabrero, David ^b   Escolano, Manuel ^c   Montesinos, Manel ^d  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c Public Health Department of Valencia   (Spain)

^d Policlnico Valencia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA SEQUENCE; FEMALE; GYNECOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; SPAIN; VIRUS DETECTION; WART VIRUS; ADOLESCENT; ALPHAPAPILLOMAVIRUS; CHI SQUARE DISTRIBUTION; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; OUTPATIENT DEPARTMENT; PAPILLOMAVIRUS INFECTIONS; VAGINA; VIROLOGY;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; AMBULATORY CARE FACILITIES; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; FEMALE; GYNECOLOGY; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; SPAIN; VAGINA;

EID: 77953236147     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365541003602056     Document Type: Article

References (39)

1. Parkin D M, Bray F. In: Chapter 2: the burden of HPVrelated cancers. Vaccine 2006;24(Suppl 3):S11-S25.
2. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev Cancer 2002;2: 342-350
3. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nature Rev Cancer 2006;6:753-763
4. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 2006;110:525-541
5. De Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17-27.
6. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527
7. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19
8. Bosch FX, de Sanjose S. In: Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003;31:3-13.
9. De Sanjose S, Almirall R, Lloveras B, Font R, Diaz M, Muñoz N, et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003;10:788-793
10. De Sanjosé S, Alemany L, Castellsagué X, Bosch FX. Human papillomavirus vaccines and vaccine implementation. Womens Health (Lond Engl) 2008;4:595-604.
11. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-1651
12. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebocontrolled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-278
13. The European Medicines Agency. EPARs for authorised medicinal products for human use. Gardasil: European Public Assessment Report. Available at: http://www.emea.europa. eu/humandocs/Humans/EPAR/gardasil/gardasilM2.htm (accessed October 23, 2009).
14. El Consejo Interterritorial aprueba la inclusión de la vacuna del virus del papiloma humano en el calendario vacunal del SNS por unanimidad. Ministry of Health, Government of Spain. Press release: [14]. http://www.msc.es/gabinete Prensa/notaPrensa/desarrolloNotaPrensa.jsp?id- 992 (accessed January 23, 2010).
15. Martorell M, Gil-Salom M, Pérez-Vallés A, Garcia JA, Rausell N, Senpere A. Presence of human papillomavirus DNA in testicular biopsies from non obstructive azoospermic men. Arch Pathol Lab Med 2005;129:1132-1136
16. Szuhai K, Sandhaus E, Kolkman-Uljee SM, Lemaître M, Truffert JC, Dirks RW, et al. A novel strategy for human papillomavirus detection and genotyping with SybrGreen and molecular beacon polymerase chain reaction. Am J Pathol 2001;159:1651-1660
17. National Center for Biotechnology Information. Basic Local Alignment Search Tool. Available at: http://www.ncbi.nlm. nih.gov/BLAST (accessed January 23, 2010).
18. Feoli-Fonseca JC, Oligny LL, Yotov WV. New method for automatic identification and typing of single and multiple superimposed human papillomavirus sequences. Diagn Mol Pathol 1999;8:216-221
19. Spanish Statistical Institute, Government of Spain. Census 2007. Available at: http://www.ine.es (accessed January 23, 2010).
20. Ortiz M, Torres M, Muñoz L, Fernández-García E, Canals J, Cabornero AI, et al. Oncogenic human papillomavirus (HPV) type distribution and HPV type 16 E6 variants in two Spanish population groups with different levels of HPV infection risk. J Clin Microbiol 2006;44:1428-1434
21. Agorastos T, Dinas K, Lloveras B, Bosch FX, Kornegay JR, Bontis JN, et al. Cervical human papillomavirus infection in women attending gynaecological outpatient clinics in northern Greece. Eur J Cancer Prev 2004;13:145-147
22. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T. et al. Population-based prevalence, type- and agespecific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008;123:1864-1870
23. Ronco G, Prado RB, Luzoro AV, Ampuero SL, Snijders PJ, Meijer CJ, et al. Prevalence of human papillomavirus infection in women in Turin, Italy. Eur J Cancer 2005;41:297-305.
24. Boulanger JC, Sevestre H, Bauville E, Ghighi C, Harlicot JP, Gondry J. Epidemiology of HPV infection. Gynecol Obstet Fertil 2004;32:218-223
25. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer 2009;45:2632-2639
26. Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, et al. Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 2003;103:413-421 (Pubitemid 36076436)
27. Sukvirach S, Smith JS, Tunsakul S, Muñoz N, Kesararat V, Opasatian O, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003;187:1246-1256
28. Pham TH, Nguyen TH, Herrero R, Vaccarella S, Smith JS, Nguyen Thuy TT, et al. Human papillomavirus infection among women in South and North Vietnam. Int J Cancer 2003;104:213-220 (Pubitemid 36249797)
29. Dai M, Bao YP, Li N, Clifford GM, Vaccarella S, Snijders PJ, et al. Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. Br J Cancer 2006;95:96-101. (Pubitemid 43980561)
30. Franceschi S, Rajkumar R, Snijders PJ, Arslan A, Mahé C, Plummer M, et al. Papillomavirus infection in rural women in southern India. Br J Cancer 2005;92:601-606 (Pubitemid 40395546)
31. Molano M, Posso H, Weiderpass E, van den Brule AJ, Ronderos M, Franceschi S, et al.; HPV Study Group. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002;87: 324-333
32. Matos E, Loria D, Amestoy GM, Herrera L, Prince MA, Moreno J, et al.; Proyecto Concordia Collaborative Group. Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study. Sex Transm Dis 2003;30:593-599
33. Ferreccio C, Prado RB, Luzoro AV, Ampuero SL, Snijders PJ, Meijer CJ, et al. Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomarkers Prev 2004; 13:2271-2276
34. Baay MF, Kjetland EF, Ndhlovu PD, Deschoolmeester V, Mduluza T, Gomo E, et al. Human papillomavirus in a rural community in Zimbabwe: the impact of HIV co-infection on HPV genotype distribution. J Med Virol 2004;73:481-485
35. Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 2004;90:638-645 (Pubitemid 38297204)
36. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297: 813-819
37. Didelot-Rousseau MN, Courgnaud V, Nagot N, Ouedraogo A, Konate I, Mayaud P, et al. Comparison of INNO-LiPA HPV Genotyping v2 with PCR product subcloning and sequencing for identification of genital human papillomavirus genotypes in African women. J Virol Methods 2006; 135:181-185
38. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 2007;17:1195-1201
39. Gharizadeh B, Ghaderi M, Donnelly D, Amini B, Wallin KL, Nyrén P. Multiple-primer DNA sequencing method. Electrophoresis 2003;24:1145-1151